

1148498

**To:** (10)(2e) (10)(2e) @minvws.nl; Bruinsma, S.W.F.H. (Erik) (10)(2e) @minvws.nl  
**From:** 5.1.2e 5.1.2e  
**Sent:** Thur 7/9/2020 10:37:40 AM  
**Subject:** FW: Request for a meeting with Executive VP for AstraZeneca Europe

**Van:** (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>  
**Datum:** donderdag 09 jul. 2020 9:36 AM  
**Aan:** @bmg.bund.de <(10)(2e) @bmg.bund.de>, Berg, A. (Angélique) <(10)(2e) @minvws.nl>, (10)(2e) @ec.europa.eu  
 (10)(2e) @ec.europa.eu, (10)(2e) @aemps.es <(10)(2e) @aemps.es>, (10)(2e) @bmg.bund.de  
 (10)(2e) @bmg.bund.de, (10)(2e) @sanita.it <(10)(2e) @sanita.it>, (10)(2e) @ec.europa.eu  
 (10)(2e) @ec.europa.eu, (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>, (10)(2e) @ec.europa.eu  
 (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>, (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>  
 (10)(2e) @pmi.gov.fr <(10)(2e) @pmi.gov.fr>, (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>  
 (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>, (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>  
 (10)(2e) @ec.europa.eu, (10)(2e) @pvh.gov.pl <(10)(2e) @pvh.gov.pl>, (10)(2e) @ec.europa.eu  
 (10)(2e) @ec.europa.eu, (10)(2e) @gov.se <(10)(2e) @gov.se>, (10)(2e) @ec.europa.eu  
 (10)(2e) @ec.europa.eu, (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>  
**Onderwerp:** FW: Request for a meeting with Executive VP for AstraZeneca Europe

fyi

**From:** (10)(2e) <(10)(2e) @astrazeneca.com> On Behalf Of (10)(2e)  
**Sent:** Thursday, July 9, 2020 9:05 AM  
**To:** 5.1.2e 5.1.2e (SANTE) <(10)(2e) @ec.europa.eu>  
**Cc:** (10)(2e) <(10)(2e) @astrazeneca.com>  
**Subject:** Request for a meeting with Executive VP for AstraZeneca Europe

Dear Ms. Gallina,

I write to you as (10)(2e) for AstraZeneca, and I would like to congratulate you on your new position. Healthcare is a fascinating field and you have joined in very challenging times, for which I wish you all the best.

AstraZeneca is a global science-led biopharmaceutical company, pushing the boundaries of science to deliver life-changing medicines, helping to transform diseases like cancer, respiratory and metabolic disorders from acute to chronic conditions and enabling patients to live longer, healthier lives. We employ 70 600 people worldwide and spend \$6 billion a year in R&D (2019).

As we are faced with the current pandemic, AstraZeneca is working around the clock to contribute to the fight against COVID-19 through accelerated R&D programs to identify possible treatments for COVID-19, as well as through our partnership with Oxford University to develop, manufacture and distribute a potential vaccine.

We are working with governments and international organisations to bring this vaccine – if successful – to patients as fast as possible and to make it affordable for healthcare systems by providing this at no profit during the pandemic, and to ensure a fair and equitable distribution. In this context and as you know, we have recently signed an agreement with the Inclusive Vaccines Alliance (IVA), to ensure production and distribution of up to 400 million doses. AstraZeneca welcomes the Commission taking over the funding agreement of our initial collaboration with the IVA's Vaccine Strategy proposal as well as the recent EU Vaccines Strategy, and I hope this can build on the groundwork from the four IVA countries.

I would be grateful for the opportunity to discuss with you how to best reach our shared objective of making this potential vaccine available to those who need it most across Europe. I will ensure follow up with your team to explore your interest and availability to meet.

Best regards,

(10)(2e)

---

**Confidentiality Notice:** This message is private and may contain confidential and proprietary information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this message is not permitted and may be unlawful.